Citations

Clear

4610 citation(s) found for "Lu, Brian".

Evaluating Physician Concordance in Interpretation of Tracheobronchomalacia Diagnosis and Phenotyping Using Dynamic Expiratory Chest Computed Tomography
Cortes-Puentes, Gustavo A. , Matatko, M., Bartholmai, Brian J. , Edell, Eric S. , Bartholmai, Brian J , Lim, Kaiser G.

Mayo Clinic

No container title available | December 20, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5105444/v1 Get It

Abstract Background: Tracheobronchomalacia (TBM) presents diagnostic challenges due to its nonspecific symptoms and variability in diagnostic methods. This study evaluates physician concordance in TBM diagnosis and phenotyping using chest computed tomography (CT) scans with dynamic expiratory views. Methods: We conducted a retrospective cross-sectional study at Mayo Clinic Rochester, analyzing 150 patients with dynamic expiratory CT scans. Three specialists—a thoracic radiologist, a bronchoscopist, and a pulmonologist—reviewed identical CT scans, blinded to prior interpretations. Inter-rater agreement was assessed using Fleiss's Kappa for TBM diagnosis and Cohen's Kappa for TBM phenotype classification into six categories: No TBM, Excessive Dynamic Airway Collapse (EDAC), Crescent Type, Circumferential Type, Saber-Sheath Type, and Mixed Type. Results: Among the 150 patients, 54 (36%) were diagnosed with TBM or EDAC. TBM was more prevalent in males, older individuals, and smokers. Agreement among specialists was substantial for TBM diagnosis (Fleiss’s Kappa = 0.61, p < 0.001) but moderate for phenotype classification (Fleiss’s Kappa = 0.52, p < 0.001). The highest concordance was between the thoracic radiologist and the pulmonologist (Cohen's Kappa = 0.68), while the lowest was between the bronchoscopist and other specialists. Conclusion: There is substantial agreement in TBM diagnosis using chest CT scans with dynamic expiratory views, but moderate variability in phenotyping. Standardizing criteria and integrating pulmonary function testing could enhance diagnostic consistency and clinical relevance.
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Shore, Neal D. , Nielsen, Sarah M. , Esplin, Edward D. , Antonarakis, Emmanuel S. , Barata, Pedro C. , Beltran, Himisha , Bryce, Alan H. , Cookson, Michael S. , Crawford, E. David , Dorff, Tanya B. , George, Daniel J. , Heath, Elisabeth I. , Hussain, Maha , McKay, Rana R. , Ross, Ashley E. , Shen, John , Sieber, Paul , Armstrong, Andrew J. , Antonarakis, Emmanuel S. , Shore, Neal , Beer, Tomasz M , Beltran, Himisha , Bryce, Alan H , Dorff, Tanya , George, Daniel J , Heath, Elisabeth I , Helfand, Brian T. , Hussain, Maha H A , McKay, Rana R , Morgans, Alicia K , Morris, Michael J , Ross, Ashley E , Sartor, A Oliver , Wise, David R , Armstrong, Andrew J , Barata, Pedro , Antonarakis, Emmanuel S , Esplin, Edward D , Antonarakis, Emmanuel S , Beer, Tomasz M. , Morgans, Alicia K. , Morris, Michael J. , Paller, Channing J. , Sartor, Oliver , Smith, Matthew Ryan

Mayo Clinic

JCO Oncology Practice | December 19, 2024 | Volume: 21 | Issue: 6 | Pages: 747-753

10.1200/op-24-00626 | PMID 39700441 Get It

Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
A Prospective, Randomized, Noninferiority Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation Compared with Standard Ureteroscopy: 30-Day Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett A. , Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Cuellar, David, Cobb, Kaitlan, Barsky, Robert I, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Chi, Thomas , Johnson, Brett , Stern, Karen L , Mueller, Thomas J. , Jones, Loren, White, Mark, Levin, Michael

Mayo Clinic

Journal of Endourology | December 19, 2024 | Volume: 39 | Issue: 1 | Pages: 10-18

10.1089/end.2024.0602 | PMID 39699687 Get It

Purpose: We report the first multicenter, prospective, randomized noninferiority controlled trial of steerable ureteroscopic renal evacuation (SURE) for nephrolithiasis treatment. Materials and Methods: Candidates for laser lithotripsy ≥18 years with ≥1 renal stone ≥7 mm and 7–20 mm stone burden were randomized 1:1 SURE vs ureteroscopy (URS). SURE was performed using the CVAC Aspiration System, a novel steerable irrigation–aspiration catheter. The primary efficacy end point was noninferiority in stone-free rate (SFR) based on zero residual fragments (RFs) 30 days postprocedure on noncontrast computed tomography. Secondary end points were superiority tests, stone clearance (percent stone volume reduction), residual stone volume (RSV), SFR (no RF >2 mm), and SFR (no RF >4 mm) 30 days postprocedure. Results: Of the subjects, 123 were randomized and 101 qualified for efficacy analysis (SURE 46 vs URS 55). Despite randomization, baseline URS stone volume was higher (SURE 485.0 ± 432.5 mm 3 vs URS 713.3 ± 558.5 mm 3 ). The primary noninferiority end point was achieved (SURE SFR 48% vs URS SFR 49%, p = 0.027, −1.3% [90% confidence interval; −18%, 15%]). Stone clearance was significantly higher for SURE vs URS subjects (SURE 96.9 ± 5.6% vs URS 92.9 ± 11.6%, p = 0.036); RSV was significantly lower (SURE 14.3 ± 3 0.9 mm 3 vs URS 70.2 ± 144.9 mm 3 , p = 0.012). SURE stone clearance and RSV were independent of baseline stone volume, but for URS degraded with increasing baseline stone volume. Safety was comparable between groups. Conclusions: SFR for SURE subjects was noninferior compared with URS subjects; stone clearance and RSV were significantly better with SURE, independent of baseline stone volume.
Seizure Detection and Lateralization Using Thalamic Deep Brain Stimulator Recordings
Ortiz‐Guerrero, Gloria , Park, Sihyeong , Starnes, Keith , Brinkmann, Benjamin H. , Gregg, Nicholas M. , Brinkmann, Benjamin H , Gregg, Nicholas M , Ortiz-Guerrero, Gloria , Starnes, Donnie Keith , Lundstrom, Brian N. , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

Journal of Clinical Neurophysiology | December 18, 2024 | Volume: 42 | Issue: 3 | Pages: 279-283

10.1097/wnp.0000000000001137 | PMID 39690452 Get It

Summary: The lack of reliable seizure detection remains a significant challenge for epilepsy care. A clinical deep brain stimulation (DBS) system provides constrained ambulatory brain recordings; however, limited data exist on the use of DBS recordings for seizure detection and lateralization. We present the case of an 18-year-old patient with drug-resistant focal epilepsy, who had seizure detection and lateralization by DBS recordings. Prior stereotactic-EEG, including a thalamus lead, identified independent left orbitofrontal and mesial temporal onset seizures. Notably, low-frequency thalamic ictal power was significantly elevated relative to baseline awake and sleep states. The patient was subsequently implanted with an anterior nucleus of the thalamus DBS system. Postimplantation, low-frequency power-in-band (5.3–10.3 Hz) recordings were initiated. Nursing staff identified four typical clinical seizures during the inpatient DBS recording period. Thalamic DBS trends contained relative peaks that were coincident with each nurse-reported seizure. Peri-ictal power was uniformly maximal ipsilateral to the seizure network. This case demonstrates the feasibility of seizure detection and lateralization by a thalamic DBS system for some individuals, and suggests DBS sensing parameter selection may be guided by thalamic stereotactic EEG. Further research is necessary to assess the generalizability of DBS seizure detection across individuals and diverse seizure networks.
Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database
Osei, Samuel Prince , Akomaning, Edwin , Florut, Teodora Francesca, Lacy, Brian E. , Bhagavathula, Akshaya Srikanth , Aldhaleei, Wafa A , Bhagavathula, Akshaya Srikanth , Sodhi, Mohit , Aldhaleei, Wafa Ali

Mayo Clinic

Diagnostics | December 16, 2024 | Volume: 14 | Issue: 24 | Pages: 2829

10.3390/diagnostics14242829 | PMID 39767190 Get It

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS). Methods: This retrospective pharmacovigilance study used the US FDA FAERS database (2007–2023). We searched GLP-1 RA medications, AEs, and adverse outcomes. Demographic, treatment indication, and AE data were collected. Descriptive analysis involved frequencies and percentages, while reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multivariate logistic regression were used to analyze GLP-1 RA-related GI AEs and outcomes. Results: From 2007 to 2023, a total of 187,757 AEs were reported with GLP-1 RAs, and 16,568 were GLP-1 RA-associated GI AEs in the US. Semaglutide was linked to higher odds of nausea (IC025: 0.151, βCoeff: 0.314), vomiting (IC025: 0.334, βCoeff: 0.495), and delayed gastric emptying (IC025: 0.342, βCoeff: 0.453). Exenatide was associated with pancreatitis (IC025: 0.601, βCoeff: 0.851) and death (ROR: 4.50, IC025: 1.101). Overall, semaglutide had a broader range of notable adverse effects; by comparison, dulaglutide and liraglutide use was associated with fewer significant GI AEs. Conclusions: Analysis of the FAERS data reveals that GLP-1 RAs, particularly semaglutide and exenatide, are significantly associated with specific GI AEs, such as nausea, vomiting, delayed gastric emptying, and pancreatitis. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. This study demonstrated the utility of pharmacovigilance data in identifying safety signals, which can inform future pharmacoepidemiological investigations to confirm causal relationships. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety.
Effect of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction Across the Age Spectrum in PARAGON-HF
Claggett, Brian, Chatur, Safia , O’Meara, Eileen , Rouleau, Jean L. , Redfield, Margaret M. , Lam, Carolyn, Packer, Milton, Shah, Amil M. , Čikeš, Maja , Pfeffer, Marc A., Solomon, Scott D. , Redfield, Margaret, Shah, Amil , Wang, Xiaowen , Vardeny, Orly , Claggett, Brian , Vaduganathan, Muthiah , Hegde, Sheila M. , Skali, Hicham , Pabón, Maria A. , Foà, Alberto , Kosztin, Annamária , Lam, Carolyn S.P. , Zile, Michael R. , Packer, Milton , Gori, Mauro , Merkely, Béla , McMurray, John J.V. , Solomon, Scott David

Mayo Clinic

European Journal of Heart Failure | December 15, 2024 | Volume: 27 | Issue: 1 | Pages: 96-106

10.1002/ejhf.3535 | PMID 39675788 Get It

Abstract Aims To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial. Methods and results A total of 4796 participants ≥50 years of age with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) ≥45% were divided into three age groups: &lt;65 years (n = 825), 65–74 years (n = 1772), and ≥75 years (n = 2199). Echocardiograms of 1097 patients were analysed in a standardized fashion at a core imaging laboratory. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death. Older patients were more likely to experience primary composite outcomes (compared to patients &lt;65 years, adjusted rate ratio [aRR] for ≥75 years: 1.39, 95% confidence interval [CI] 1.21–1.61), total HF hospitalization (aRR 1.27, 95% CI 1.09–1.49), and CV death (adjusted hazard ratio [aHR] 2.04, 95% CI 1.44–2.87). Age did not modify the effect of sacubitril/valsartan compared to valsartan on primary composite endpoint (pinteraction = 0.79) in the overall population or in those with LVEF ≤57%. Older adults randomized to sacubitril/valsartan were more likely to develop hypotension compared to those receiving valsartan (pinteraction = 0.026). Older patients had smaller left ventricular chamber sizes, higher LVEF, and were more likely to have abnormal measures of diastolic function. Conclusion Older patients with HF with preserved ejection fraction had higher event rates than younger patients, more adverse events overall, and more hypotension when treated with sacubitril/valsartan; however, the treatment benefits of sacubitril/valsartan were retained in older patients.
An international Delphi consensus on patient preparation for metabolic and bariatric surgery
Clyde, Danielle , Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Catalain, Copaescu, Clare, Ken , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Ghanem, Omar M. , Hopkins, George, Kothari, Shanu N. , Kow, Lilian , Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Saliminen, Paulina, Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Tahrani, Abd A. , Voon, Kelvin , Welbourn, Richard , Lamb, Peter , Mahawar, Kamal , Yang, Wah , Salminen, Paulina , Kermansaravi, Mohammad , Zerrweck, Carlos , Yang, Wah , Byrne, James Patrick , Cameron, David, Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Husain, Farah Anwari , Joyce, Brian, Miras, Alexander Dimitri , Moussa, Osama , Neto, Manoel Galvão , Parmar, Chetan D. , Peterli, Ralph , Stenberg, Erik , Vilallonga, Ramón , Robertson, Andrew G.

Mayo Clinic

Clinical Obesity | December 14, 2024 | Volume: 15 | Issue: 2 | Pages: No page available

10.1111/cob.12722 | PMID 39673462 Get It

SummaryGlobal obesity rates have risen dramatically, now exceeding deaths from starvation. Metabolic and bariatric surgery (MBS), initially for severe obesity (BMI ≥35 kg/m2), is performed globally over 500 000 times annually, offering significant metabolic benefits beyond weight loss. However, varying eligibility criteria globally impact patient care and healthcare resources. Updated in 2022, ASMBS and IFSO guidelines aim to standardise MBS indications, reflecting current understanding and emphasising comprehensive preoperative assessments. Yet, clinical variability persists, necessitating consensus‐based recommendations. This modified Delphi study engaged 45 global experts to establish consensus on perioperative management in MBS. Experts selected from bariatric societies possessed expertise in MBS and participated in a two‐round Delphi protocol. Consensus was achieved on 90 of 169 statements (53.3%), encompassing multidisciplinary team composition, patient selection criteria, preoperative testing, and referral pathways. The agreement highlighted the critical role of comprehensive preoperative assessments and the integration of healthcare professionals in MBS. These findings offer essential insights to standardise perioperative practices and advocate for evidence‐based guidelines in MBS globally. The study underscores the need for unified protocols to optimise outcomes and guide future research in MBS.
Rehabilitation practices during hematopoietic stem cell transplantation: An international survey
Oza, Sonal , Barksdale, Touré, Herbert, Aliea, Bansal, Vishal , McCourt, Orla , Aljurf, Mahmoud , Leite, Victor F , Parke, Sara C. , Bansal, Vishal, Jeon, Jae Yong , Morishita, Shinichiro , Fu, Jack Brian , Ngo‐Huang, An

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | December 11, 2024 | Volume: 17 | Issue: 3 | Pages: 176-183

10.4103/hemoncstem.hemoncstem-d-24-00007 | PMID 39412753 Get It

Background and Objective Rehabilitation therapy plays an important role in treating physical and functional impairments observed in individuals undergoing hematopoietic stem cell transplants (HSCT). This study assessed the rehabilitation practices implemented in the HSCT population internationally. Materials and Methods A 48-question online survey comprising questions soliciting information regarding patient characteristics, therapy details (timing, indication, and administering providers), outcome measures, and precautions were developed by an international group of cancer rehabilitation physicians. As reported by European registries, surveys were administered to personnel providing care to patients receiving HSCT at cancer centers, which comprised the top 10% of HSCT volume. In addition, emails were sent to National Medical Societies and registries in the Latin America, Asia, and Pacific regions. Results Forty-three institutions from 18 countries responded to the survey. Half of the centers provided referrals for rehabilitation therapy at the time of admission. Referrals were provided for functional decline (84.5%), risk of falls (53.3%), and discharge planning (42.2%). Rehabilitation therapies were administered by physical therapists (93.0%), occupational therapists (34.9%), therapy aides (14.0%), and speech-language pathologists (11.6%). Approximately 95% of the surveyed centers used objective functional measures such as sit-to-stand (46.5%), grip strength (46.5%), and 6-min walk/gait speed (both 34.9%). The blood counts were monitored to determine the appropriateness of the therapy modalities. Conclusion Rehabilitation practices varied internationally; however, most centers provided skilled therapy during hospitalization for HSCT, utilized objective and patient-reported outcomes, and monitored blood counts to determine the safety of administering therapy.
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
Laetsch, Theodore W. , Voss, Stephan D. , Ludwig, Kathleen , Hall, David , Barkauskas, Donald A. , DuBois, Steven G. , Ronan, Joan, Rudzinski, Erin R. , Memken, Amanda , Robinson, Krystal, Sorger, Joel, Bhatla, Teena, Church, Alanna J. , Fox, Elizabeth , Weigel, Brenda J. , Voss, Stephan D , Reid, Joel M , Crompton, Brian D , Church, Alanna J , Fox, Elizabeth , Weigel, Brenda J , Teachey, David T , Reid, Joel M. , Crompton, Brian D.

Mayo Clinic

Journal of Clinical Oncology | December 9, 2024 | Volume: 43 | Issue: 10 | Pages: 1188-1197

10.1200/jco-24-01854 | PMID 39652801 Get It

PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed NTRK fusion–positive solid tumors with response-adapted duration of therapy and local control. METHODS Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability. The primary end point was the objective response rate (ORR) within six cycles in patients with infantile fibrosarcoma (IFS); patients with other histologic diagnoses were analyzed in a separate cohort. Secondary objectives included event-free survival (EFS) and overall survival (OS). RESULTS Thirty-three patients were enrolled: 18 with IFS and 15 with other solid tumors. The ORR within six cycles was 94% (17/18; 95% adjusted CI, 72.7 to 98.6) among children with IFS and 60% (9/15; 95% CI, 32.3 to 83.7) among children with other solid tumors. Six percent (2/33; 95% CI, 0.7 to 22.2) patients developed progressive disease while on therapy. Two-year EFS and OS among these groups were 82.2% (95% CI, 54.3 to 93.9) and 93.8% (95% CI, 63.2 to 99.1) for IFS and 80% (95% CI, 50.0 to 93.1) and 93.3% (95% CI, 61.3 to 99.0) for other solid tumors, respectively. Patients undergoing surgical resection of their tumor had prolonged EFS, with only 1 of 16 such patients experiencing disease progression. Four of 33 patients had dose-limiting toxicities. CONCLUSION Larotrectinib is highly active in patients with newly diagnosed NTRK fusion–positive solid tumors. Larotrectinib should be a frontline option for patients with IFS and other NTRK fusion–positive solid tumors. Local control with surgical resection remains important in the treatment of patients with IFS.